ArticleCellular and molecular life sciences : CMLS2026
SLC25A21 promotes ferroptosis by inducing mitochondrial GPX4 deficiency in colorectal cancer.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Mitochondrial 2-oxodicarboxylate carrier (SLC25A21) plays a crucial role in maintaining mitochondrial function and regulating apoptosis. Whether SLC25A21 influences cell death solely through apoptosis remains unclear. Here, we reported that mitochondrial protein Methylcrotonoyl-CoA carboxylase beta chain (MCCC2) co-localized with mitochondrial inner membrane protein SLC25A21 and promoted its lysosomal degradation in colorectal cancer (CRC) cells. The ectopic overexpression of SLC25A21 significantly inhibited the malignant behaviors of CRC cells. Overexpression of SLC25A21 induced cell death and cell cycle arrest at the G2/M phase, and triggered hallmark ferroptotic alterations, including lipid peroxidation (LPO) and reactive oxygen species (ROS) accumulation, increased Malondialdehyde (MDA) contents, GSSG/GSH and NADP + /NADPH ratios, and abnormal mitochondrial morphologies. Mechanistically, SLC25A21 formed a complex with Glutathione Peroxidase 4 (GPX4) and activated the MEK-ERK and p38 MAPK signaling pathways, together reducing the GPX4 pool in mitochondria. Treatment of CRC cells with a GPX4 agonist inhibited SLC25A21-induced ferroptosis, thereby reducing the production of LPO and ROS, and restoring partially malignant behaviors of the cells. In vivo, SLC25A21 inhibited tumor growth by activating ferroptosis. Relatively high expression of SLC25A21 was associated with unfavorable outcomes in multiple patient cohorts, suggesting a complex role for SLC25A21 in CRC progression. Together, we identified SLC25A21-GPX4 interaction as an important regulatory axis in mitochondrial redox maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.